The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers - PubMed (original) (raw)
Clinical Trial
The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers
B N van Berckel et al. Psychopharmacology (Berl). 1998 Jul.
Abstract
D-Cycloserine, a partial agonist of the glycine recognition site of the N-methyl-D-aspartate (NMDA) receptor, may serve as a probe for human cerebral NMDA receptor function. Since NMDA receptors are involved in neuroendocrine secretion, changes in pituitary secretion in response to D-cycloserine administration could serve as a model for NMDA receptor activity. The effects of an oral dose of 500 mg D-cycloserine were assessed in a neuroendocrine challenge paradigm in 20 healthy male volunteers, using a double-blind, randomized placebo-controlled crossover design. Luteinizing hormone (LH) and cortisol secretion was studied, since preclinical studies indicate that these hormones increase in response to NMDA receptor stimulation. Furthermore, plasma homovanillic acid (HVA) secretion was studied, as NMDA receptors are suggested to be involved in the regulation of dopaminergic neurotransmission. D-cycloserine was readily absorbed and did not induce side-effects or changes in vital signs and mood scores. D-Cycloserine stimulated LH secretion and induced a significant rise of the area under the plasma concentration time curve of LH. D-Cycloserine did not stimulate cortisol or plasma HVA secretion. These neuroendocrine effects suggest that D-cycloserine may be used to assess human NMDA receptor function in cerebral disorders, such as schizophrenia.
Similar articles
- Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects.
van Berckel BN, Lipsch C, Timp S, Gispen-de Wied C, Wynne H, van Ree JM, Kahn RS. van Berckel BN, et al. Neuropsychopharmacology. 1997 May;16(5):317-24. doi: 10.1016/S0893-133X(96)00196-0. Neuropsychopharmacology. 1997. PMID: 9109102 Clinical Trial. - D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, van Ree JM, Kahn RS. van Berckel BN, et al. Neuropsychopharmacology. 1999 Aug;21(2):203-10. doi: 10.1016/S0893-133X(99)00014-7. Neuropsychopharmacology. 1999. PMID: 10432468 Clinical Trial. - The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects.
van Berckel BN, Oranje B, van Ree JM, Verbaten MN, Kahn RS. van Berckel BN, et al. Psychopharmacology (Berl). 1998 Jun;137(3):271-81. doi: 10.1007/s002130050620. Psychopharmacology (Berl). 1998. PMID: 9683005 Clinical Trial. - Effects of D-cycloserine on negative symptoms in schizophrenia.
Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP. Duncan EJ, et al. Schizophr Res. 2004 Dec 1;71(2-3):239-48. doi: 10.1016/j.schres.2004.03.013. Schizophr Res. 2004. PMID: 15474895 Review. - D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.
Goff DC. Goff DC. Curr Neuropharmacol. 2017;15(1):21-34. doi: 10.2174/1570159x14666160225154812. Curr Neuropharmacol. 2017. PMID: 26915421 Free PMC article. Review.
Cited by
- Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans.
Klumpers F, Denys D, Kenemans JL, Grillon C, van der Aart J, Baas JM. Klumpers F, et al. J Psychopharmacol. 2012 Apr;26(4):471-8. doi: 10.1177/0269881111431624. Epub 2012 Feb 20. J Psychopharmacol. 2012. PMID: 22351380 Free PMC article. - Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study.
Dong Z, Grunebaum MF, Lan MJ, Wagner V, Choo TH, Milak MS, Sobeih T, Mann JJ, Kantrowitz JT. Dong Z, et al. Front Psychiatry. 2021 Jun 2;12:653026. doi: 10.3389/fpsyt.2021.653026. eCollection 2021. Front Psychiatry. 2021. PMID: 34149476 Free PMC article. - The NMDA receptor partial agonist d-cycloserine does not enhance motor learning.
Günthner J, Scholl J, Favaron E, Harmer CJ, Johansen-Berg H, Reinecke A. Günthner J, et al. J Psychopharmacol. 2016 Oct;30(10):994-9. doi: 10.1177/0269881116658988. Epub 2016 Jul 19. J Psychopharmacol. 2016. PMID: 27436230 Free PMC article. Clinical Trial. - Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
Singh SP, Singh V. Singh SP, et al. CNS Drugs. 2011 Oct 1;25(10):859-85. doi: 10.2165/11586650-000000000-00000. CNS Drugs. 2011. PMID: 21936588 - Steroid hormone secretion after stimulation of mineralocorticoid and NMDA receptors and cardiovascular risk in patients with depression.
Nowacki J, Wingenfeld K, Kaczmarczyk M, Chae WR, Salchow P, Abu-Tir I, Piber D, Hellmann-Regen J, Otte C. Nowacki J, et al. Transl Psychiatry. 2020 Apr 20;10(1):109. doi: 10.1038/s41398-020-0789-7. Transl Psychiatry. 2020. PMID: 32313032 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources